Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance
Apr 2, 2025, 11:01 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The positive earnings and sales growth beat analyst expectations, reflecting improved market conditions. Historically, similar positive reports often lead to significant stock price increases.
AI summary
What happened, with direct paths to the underlying reporting
ANGO's Q3 2025 adjusted EPS was 3 cents, surpassing a 13-cent loss estimate. Sales reached $72 million, beating expectations and up 9.2% year-over-year. Gross margin rose to 54%, a 290 basis point improvement from last year. Fiscal 2025 sales forecast is $285-$288 million, ahead of prior estimates. Stock surged 10.09% to $10.63 following the earnings report.
ANGO's Q3 2025 adjusted EPS was 3 cents, surpassing a 13-cent loss estimate.
Sales reached $72 million, beating expectations and up 9.2% year-over-year.
Gross margin rose to 54%, a 290 basis point improvement from last year.
Fiscal 2025 sales forecast is $285-$288 million, ahead of prior estimates.
Stock surged 10.09% to $10.63 following the earnings report.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
AngioDynamics reported better-than-expected quarterly earnings, showing improved financial performance. The company posted losses of 10 cents per share, beating estimates by 2 cen…
ANGO to report Q1 earnings on October 2. Projected loss of 12 cents per share indicates potential ongoing challenges. Quarterly revenue expected to rise to $72.69 million, showing…
ANGO's Q4 loss was 3 cents per share, beating expectations. Sales reached $80.2 million, exceeding consensus estimates by 8.7%. Med Tech sales rose 22% year-over-year, primarily d…
AngioDynamics reported a Q1 loss of 11 cents, better than expected. Quarterly sales were $67.491 million, slightly under expectations. ANGO shares dropped 15.6% to $6.45 following…